128 related articles for article (PubMed ID: 22089939)
1. Structure and function of von Willebrand factor.
Hassan MI; Saxena A; Ahmad F
Blood Coagul Fibrinolysis; 2012 Jan; 23(1):11-22. PubMed ID: 22089939
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
3. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D
Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314
[TBL] [Abstract][Full Text] [Related]
4. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain.
Huizinga EG; Tsuji S; Romijn RA; Schiphorst ME; de Groot PG; Sixma JJ; Gros P
Science; 2002 Aug; 297(5584):1176-9. PubMed ID: 12183630
[TBL] [Abstract][Full Text] [Related]
5. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
6. Interaction of the von Willebrand factor with platelets and thrombosis.
Perutelli P; Mori PG
Recenti Prog Med; 1997 Nov; 88(11):526-9. PubMed ID: 9401429
[TBL] [Abstract][Full Text] [Related]
7. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
[TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor without the A2 domain is resistant to proteolysis.
Lankhof H; Damas C; Schiphorst ME; Ijsseldijk MJ; Bracke M; Furlan M; Tsai HM; de Groot PG; Sixma JJ; Vink T
Thromb Haemost; 1997 May; 77(5):1008-13. PubMed ID: 9184419
[TBL] [Abstract][Full Text] [Related]
9. Structure-function relationship of the A1 domain of von Willebrand factor.
Girma JP; Ribba AS; Meyer D
Thromb Haemost; 1995 Jul; 74(1):156-60. PubMed ID: 8578449
[TBL] [Abstract][Full Text] [Related]
10. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
11. Conformational stability and domain unfolding of the Von Willebrand factor A domains.
Auton M; Cruz MA; Moake J
J Mol Biol; 2007 Feb; 366(3):986-1000. PubMed ID: 17187823
[TBL] [Abstract][Full Text] [Related]
12. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling.
Nitu-Whalley IC; Riddell A; Lee CA; Pasi KJ; Owens D; Enayat MS; Perkins SJ; Jenkins PV
Thromb Haemost; 2000 Dec; 84(6):998-1004. PubMed ID: 11154147
[TBL] [Abstract][Full Text] [Related]
13. Mouse models to study von Willebrand factor structure-function relationships in vivo.
Denis CV; Marx I; Badirou I; Pendu R; Christophe O
Hamostaseologie; 2009 Jan; 29(1):17-8, 20. PubMed ID: 19151840
[TBL] [Abstract][Full Text] [Related]
14. ASP514 within the A1 domain of bovine von Willebrand factor is required for interaction with platelet glycoprotein Ib.
Sinha D; Bakhshi M; Kunapuli S; Vora R; Gabriel JL; Kirby EP; Budzynski AZ
Biochem Biophys Res Commun; 1994 Sep; 203(2):881-8. PubMed ID: 8093071
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism and classification of von Willebrand disease.
Sadler JE; Matsushita T; Dong Z; Tuley EA; Westfield LA
Thromb Haemost; 1995 Jul; 74(1):161-6. PubMed ID: 8578450
[TBL] [Abstract][Full Text] [Related]
16. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation.
Ruggeri ZM
Best Pract Res Clin Haematol; 2001 Jun; 14(2):257-79. PubMed ID: 11686099
[TBL] [Abstract][Full Text] [Related]
17. The secondary structure of the von Willebrand factor type A domain in factor B of human complement by Fourier transform infrared spectroscopy. Its occurrence in collagen types VI, VII, XII and XIV, the integrins and other proteins by averaged structure predictions.
Perkins SJ; Smith KF; Williams SC; Haris PI; Chapman D; Sim RB
J Mol Biol; 1994 Apr; 238(1):104-19. PubMed ID: 8145250
[TBL] [Abstract][Full Text] [Related]
18. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
